THROMBOPOIETIN IN NEONATAL THROMBOCYTOPENIA

血小板减少症在患病新生儿中相对常见。 早产 婴儿它可以与诸如败血症的临床实体相关联地发生， 患有先兆子痫的母亲的生长迟缓婴儿和 产时窒息 假设婴儿患有 这些临床状况可能发展为新生儿血小板减少症， TPO的暂时缺陷正在调查中。 如果这个被发现 诚然，这些条件将适合治疗与 重组人血小板生成素，这将很快成为可用于 初步临床试验。这项研究的目的是检查和量化 血小板减少新生儿血小板生成素水平。 状态：受试者入组和数据分析已完成。

Thrombocytopenia is relatively common in sick newborn infants. In preterm infants it can occur in association with such clinical entities as sepsis, growth retarded infants of mothers with pre-eclampsia and infants who suffered from intrapartum asphyxia. The hypothesis that infants with these clinical conditions may develop neonatal thrombocytopenia from a temporary deficiency of TPO is under investigation here. If this is found to be true, these conditions would be amenable to treatment with recombinant human thrombopoietin, which will soon become available for initial clinical trials. The aim of this study is to examine and quantify thrombopoietin levels in thrombocytopenic newborns. Status: Subject enrollment and data analysis completed.